BIOFILCHEM - Biofil Chemicals
📢 Recent Corporate Announcements
Biofil Chemicals & Pharmaceuticals reported a severe decline in its financial performance for Q3 FY26, with revenue from operations crashing to ₹85.63 Lakhs from ₹1419.52 Lakhs in the same period last year. Net profit followed suit, dropping to ₹7.92 Lakhs compared to ₹16.46 Lakhs YoY. The company attributed this massive operational disruption to mandatory factory renovations and upgrades required to comply with the revised Schedule M of the Drugs & Cosmetics Rules. Consequently, the Chemicals division reported zero revenue for the quarter, while Pharma revenue saw a drastic reduction.
- Revenue from operations fell by 94% YoY to ₹85.63 Lakhs from ₹1419.52 Lakhs.
- Net Profit for the quarter declined 51.9% YoY to ₹7.92 Lakhs.
- Chemicals division revenue dropped to zero for the quarter compared to ₹139.61 Lakhs in the preceding quarter.
- Manufacturing operations were partially disrupted due to factory renovation for Schedule M compliance.
- Earnings Per Share (EPS) halved to ₹0.05 from ₹0.10 in the corresponding quarter of the previous year.
Biofil Chemicals & Pharmaceuticals Limited has responded to a surveillance query from the National Stock Exchange regarding recent significant fluctuations in its share price. The company officially stated that there are no undisclosed material developments or events that would impact the stock's valuation. Management attributed the recent price and volume volatility purely to prevailing market conditions and broader stock market scenarios. The company reaffirmed its commitment to complying with SEBI (LODR) Regulations, 2015, for all future disclosures.
- NSE issued a surveillance clarification request (Ref. No.: NSE/CM/Surveillance/16423) on February 3, 2026.
- Company confirms no material events are occurring that have not been disclosed to the exchanges.
- Price and volume movements are attributed to market-driven factors rather than company-specific news.
- Management maintains strict adherence to Regulation 30 of SEBI (LODR) Regulations, 2015.
Biofil Chemicals & Pharmaceuticals Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending December 31, 2025. The document, issued by Registrar Ankit Consultancy Private Limited, confirms that all dematerialization requests were handled according to regulatory standards. Specifically, it verifies that physical certificates were mutilated and cancelled, and the depositories' names were updated in the register within 15 days. This filing is a standard administrative requirement and indicates no operational changes.
- Quarterly compliance for the period ended December 31, 2025, successfully filed.
- Registrar confirms dematerialization requests were processed within the 15-day limit.
- Physical share certificates were verified, mutilated, and cancelled as per SEBI norms.
- The filing ensures that the company's shareholding records are accurately maintained in electronic form.
Biofil Chemicals & Pharmaceuticals Limited has announced the closure of its trading window starting January 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations for the consideration of un-audited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared to the stock exchanges. The company has also implemented PAN-level freezing for designated persons as per recent SEBI circulars.
- Trading window closure begins on Thursday, January 1, 2026.
- Closure is for the purpose of approving financial results for the period ending December 31, 2025.
- The window will reopen 48 hours after the financial results are made public.
- Compliance includes PAN-level freezing for Designated Persons (DPs) per SEBI guidelines.
- The specific date for the Board Meeting to approve results will be announced separately.
Biofil Chemicals & Pharmaceuticals Limited has paid a total fine of ₹4,24,823.60 (inclusive of GST) to BSE Limited due to non-compliance with Regulation 17(1)(c) of SEBI Listing Regulations. The penalty follows two separate notices issued in August and November 2025, totaling ₹3.60 lakh in principal fines. Despite filing a waiver application, the company settled the dues 'under protest' on December 2, 2025. The company stated that this development has no material impact on its financial or operational activities.
- BSE imposed an initial fine of ₹95,000 on August 29, 2025, for non-compliance with board composition norms.
- An additional fine of ₹2,65,000 was levied on November 28, 2025, for continued regulatory lapses.
- Total payment of ₹4,24,823.60 (including GST) was made by the company on December 2, 2025.
- The company has filed waiver applications with both NSE and BSE which are currently under process.
- Non-compliance pertains to Regulation 17(1)(c) regarding the minimum number of directors on the board.
Financial Performance
Revenue Growth by Segment
Total turnover decreased by 16.82% to INR 3370.74 lacs in FY25 compared to INR 4052.50 lacs in FY24. The Pharma Unit revenue fell 4.33% to INR 2666.03 Lacs, while the Chemicals Unit revenue saw a significant decline of 44.59% to INR 674.18 Lacs.
Geographic Revenue Split
100% of operations are conducted within India; the company reported no separate geographical segments in its financial disclosures.
Profitability Margins
Operating profit margin improved from 2.25% to 2.61% YoY. Net profit margin also saw a slight increase from 1.82% to 1.91%, despite a 35.79% drop in absolute net profit to INR 57.87 lacs.
EBITDA Margin
Operating profit margin stood at 2.61% for FY25, up from 2.25% in FY24, indicating a slight improvement in core operational efficiency despite lower overall sales volumes.
Capital Expenditure
The company is currently divesting assets rather than expanding, having sold plant, machinery, and leasehold land at its Sanwer Road unit to Cyano Pharma and Formo Plast. It also proposed the disposal of 80,156 square meters of leasehold rights at Pithampur to consolidate operations.
Credit Rating & Borrowing
The company maintains a very low Debt-Equity ratio of 0.03 (up from 0.02) and a strong Interest Coverage Ratio of 24.14, indicating minimal reliance on external debt and high capacity to service interest from earnings.
Operational Drivers
Capacity Expansion
The company is pursuing a consolidation strategy rather than expansion, moving operations to a single location to optimize resources. It is disposing of its Sanwer Road assets and a vacant 80,156 sq meter portion of industrial land in Pithampur.
Raw Material Costs
Cost of Goods Sold increased in FY25 due to higher purchase of goods, which contributed to a 47.47% decrease in the inventory turnover ratio.
Manufacturing Efficiency
The company is focusing on enhancing efficiency through consolidation; however, inventory turnover dropped from 19.93 to 10.47 (-47.47%), indicating a temporary slowdown in moving stock.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth is targeted through the consolidation of operations to reduce overheads, a focus on new product launches in the generics and branded markets, and increasing volume growth to capitalize on improved demand in the domestic pharma sector.
Products & Services
Pharmaceutical products (generics and branded) and Chemical products.
Brand Portfolio
Biofil
New Products/Services
The company is focusing on new product launches in the generics and branded segments to drive mid-teen growth in the 2025-2026 period.
Market Expansion
Focusing on domestic-focused growth with a pick-up in volume for generics and branded products.
Strategic Alliances
The company entered into agreements to sell assets to Cyano Pharma Private Limited and Formo Plast Private Limited as part of its operational restructuring.
External Factors
Industry Trends
The pharma sector is growing due to improved US generics performance and raw material cost moderation. Domestic companies are expected to see mid-teen growth (approx 15%) in FY26 driven by new launches and volume gains.
Competitive Landscape
The company operates in a competitive domestic pharma market where success depends on product launch speed and volume growth.
Competitive Moat
The company's moat is based on its multi-segment presence in both Pharma and Chemicals and its low-debt profile (0.03 D/E), which provides financial stability during market downturns.
Macro Economic Sensitivity
The company is sensitive to global and domestic economic factors, including the performance of the US generics market and fluctuations in raw material costs.
Consumer Behavior
Increased demand for branded products and generics is a key trend driving the company's current product strategy.
Geopolitical Risks
Global economic factors are cited as risks that could materially influence operations, particularly in the pharmaceutical export and generics markets.
Regulatory & Governance
Industry Regulations
Operations are governed by SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Indian Accounting Standards (Ind-AS).
Legal Contingencies
The company faced a fine of INR 95,000 imposed by stock exchanges (BSE/NSE) for delays in regulatory submissions/disclosures.
Risk Analysis
Key Uncertainties
The 44.59% drop in Chemical segment revenue and the 37.40% decrease in debtors' turnover indicate significant risks in revenue stability and cash flow collection efficiency.
Geographic Concentration Risk
100% concentration in the Indian market, specifically with manufacturing roots in Madhya Pradesh.
Technology Obsolescence Risk
The company is addressing operational efficiency through consolidation but has not detailed specific digital or R&D technology shifts.
Credit & Counterparty Risk
The decrease in debtors' turnover to 0.94 suggests a potential risk in the quality of receivables or a significant extension of credit terms to customers.